Advances in disease biology
Advances in the management of B and T-cell lymphoid malignancies
Approaches to treating PV patients
AYA MPNs: pregnancy, thromboses, unique aspects
Cardiovascular assessment: how and when?
CAR therapies
Chemotherapy regimens
CHIP and inflammation in MPNs
Complications of the treatment of hematological diseases
Current clinical trials in MDS
Cytopenias
Essential thrombocytosis: state-of-the-art
FLT3 inhibitors
How to treat CALR ET – what about IPSET?
HR-MDS
Immunotherapy (eg. bispecific antibodies, cellular therapies, etc.)
Impact of new cellular therapy treatments: CAR-T cells
IPSS-M for MDS
Maintenance therapy for post allogeneic transplant in AML
Minimal residual disease monitoring and use in practice
Molecular monitoring
Myelofibrosis: current and novel approaches
NHL and CLL
Options for refractory diseases
Rare MPNs – focus on emerging subtypes
Role of future of pathology and molecular markers in MPNs
Therapeutic decisions based on MRD and AML